Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer

Oxaliplatin (OX) and irinotecan (IRI) are used as key drugs for the first‐line treatment of metastatic colorectal cancer (mCRC). However, no biomarkers have been identified to decide which of the drugs is initially used. In this translational research (TR) of the TRICOLORE trial, the advanced colore...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shin, Sakamoto, Yasuhiro, Denda, Tadamichi, Takashima, Atsuo, Komatsu, Yoshito, Nakamura, Masato, Ohori, Hisatsugu, Yamaguchi, Tatsuro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Amagai, Kenji, Kondo, Hitoshi, Shimada, Ken, Sato, Atsushi, Yuki, Satoshi, Okita, Akira, Ouchi, Kota, Komine, Keigo, Watanabe, Mika, Morita, Satoshi, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019218/
https://www.ncbi.nlm.nih.gov/pubmed/33548159
http://dx.doi.org/10.1111/cas.14841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019218/
https://www.ncbi.nlm.nih.gov/pubmed/33548159
http://dx.doi.org/10.1111/cas.14841

Ejemplares similares